Hutchmed (China) Limited Grant of Share Options, and Awards under LTIP (5628K)
02 Septembre 2021 - 1:45PM
UK Regulatory
TIDMHCM
RNS Number : 5628K
Hutchmed (China) Limited
02 September 2021
Grant of Share Options under Share Option Scheme and Awards
under Long Term Incentive Plan
Hong Kong, Shanghai, & Florham Park, NJ: Thursday ,
September 2 , 2021: HUTCHMED (China) Limited ("HUTCHMED")
(Nasdaq/AIM: HCM; HKEX: 13) announces that on September 1, 2021 ,
it granted share options under the Share Option Scheme adopted by
HUTCHMED in 2015 as refreshed in April 2020 (the "Share Option
Scheme") and conditional awards ("LTIP Awards") under the Long Term
Incentive Plan adopted by HUTCHMED in 2015 ("LTIP") .
Aimed at attracting and retaining top talent, the Remuneration
Committee of HUTCHMED appointed an independent advisor to conduct a
compensation benchmarking research on peer group U.S. and China
biotech companies. The Remuneration Committee comprehensively
reviewed the compensation and share-based incentives policies of
HUTCHMED and its subsidiaries (the "Group") and established an
attractive policy to ensure the Group is able to recruit and retain
top talent. Vesting of share-based awards under the policy is in
line with that peer group.
HUTCHMED granted share options under its Share Option Scheme to
18 employees to subscribe for a total of 1,086,000 Ordinary Shares
represented by 217,200 American Depositary Shares ("ADSs", each
equating to five Ordinary Shares) subject to the acceptance of the
grantee. Details of such share options granted prescribed are as
follows:
Date of grant : September 1, 2021
Exercise price of share options : US$39.74 per ADS (equivalent to
granted HK$62.00 per Ordinary Share at the
conversion rate HK$7.8=US$1) (such
exercise price has been determined
by reference to the price of the
Ordinary Shares on The Stock Exchange
of Hong Kong Limited ("HKEX"))
Number of share options granted : 1,086,000 represented by 217,200
ADSs (five share options shall entitle
the holder thereof to subscribe
for one ADS)
Closing market price of ordinary : US$39.74 per ADS (equivalent to
shares at HKEX on the date of HK$62.00 per Ordinary Share at the
grant conversion rate HK$7.8=US$1)
Validity period of the share : From September 1, 2021 to August
options 31, 2031
At the same time, HUTCHMED also granted three employees of the
Group with non-performance LTIP Awards, and 119 employees of the
Group with performance-related LTIP Awards.
None of the grantees is a director, chief executive nor
substantial shareholder of the Company, or an associate (as defined
under the Rules Governing the Listing of Securities on The Stock
Exchange of Hong Kong Limited) of any of them.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. A dedicated organization of over 1,400
personnel has advanced eleven cancer drug candidates from in-house
discovery into clinical studies around the world, with its first
three oncology drugs now approved and marketed. For more
information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Forward - Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
HUTCHMED's filings with the U.S. Securities and Exchange
Commission, on AIM and on HKEX. HUTCHMED undertakes no obligation
to update or revise the information contained in this announcement,
whether as a result of new information, future events or
circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, +1 (917) 570 7340 (Mobile)
Solebury Trout bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
FTI Consulting 545 055 (Mobile)
HUTCHMED@fticonsulting.com
Asia - Zhou Yi, +852 9783 6894 (Mobile)
Brunswick HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSSLFFEEFSEDU
(END) Dow Jones Newswires
September 02, 2021 07:45 ET (11:45 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
